Nuwellis Inc
NUWE0.308USD
-0.060-16.45%
Market hours （ET）Quotes delayed by 15 min
1.35MMarket Cap
LossP/E TTM
More Details of Nuwellis Inc Company
Nuwellis, Inc. is a commercial-stage medical technology company. The Company is focused on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy, including the Aquadex FlexFlow and the Aquadex SmartFlow systems (collectively the Aquadex System). The Aquadex SmartFlow system is indicated for temporary or extended use in adult and pediatric patients weighing 20 kilograms or more whose fluid overload is unresponsive to medical management, including diuretics. The Aquadex System is designed to remove excess fluid from patients suffering from fluid overload who have failed diuretic therapy. The Aquadex System consists of a console, which is a piece of equipment containing electromechanical pumps and a liquid crystal display (LCD) screen; a one-time disposable blood circuit set, which is an integrated collection of tubing, filters, sensors, and connectors that contain and deliver the blood from and back to the patient, and a disposable catheter.
Company Info
Ticker SymbolNUWE
Company nameNuwellis Inc
IPO dateFeb 16, 2012
Founded at2002
CEOErb (John L)
Number of employees38
Security typeOrdinary Share
Fiscal year-endFeb 16
Address12988 Valley View Rd
CityEDEN PRAIRIE
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code55344
Phone19523454200
Websitehttps://www.nuwellis.com/
Ticker SymbolNUWE
IPO dateFeb 16, 2012
Founded at2002
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Archelle (Feldshon) Georgiou, M.D.
Dr. Archelle (Feldshon) Georgiou, M.D.
Independent Director
Independent Director
324.00
--
Mr. David Alan (Dave) Mcdonald
Mr. David Alan (Dave) Mcdonald
Independent Director
Independent Director
324.00
--
Mr. Gregory D. (Greg) Waller
Mr. Gregory D. (Greg) Waller
Independent Director
Independent Director
--
--
Mr. Robert B. (Rob) Scott
Mr. Robert B. (Rob) Scott
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Neil P. Ayotte, Esq.
Mr. Neil P. Ayotte, Esq.
Senior Vice President, General Counsel, Secretary and Chief Compliance Officer
Senior Vice President, General Counsel, Secretary and Chief Compliance Officer
--
--
Dr. Maria Rosa Costanzo, M.D.
Dr. Maria Rosa Costanzo, M.D.
Independent Director
Independent Director
--
--
Erb (John L)
Erb (John L)
Chairman of the Board, Interim President and Chief Executive Officer
Chairman of the Board, Interim President and Chief Executive Officer
--
--
Mr. Michael (Mike) Mccormick
Mr. Michael (Mike) Mccormick
Lead Independent Director
Lead Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Archelle (Feldshon) Georgiou, M.D.
Dr. Archelle (Feldshon) Georgiou, M.D.
Independent Director
Independent Director
324.00
--
Mr. David Alan (Dave) Mcdonald
Mr. David Alan (Dave) Mcdonald
Independent Director
Independent Director
324.00
--
Mr. Gregory D. (Greg) Waller
Mr. Gregory D. (Greg) Waller
Independent Director
Independent Director
--
--
Mr. Robert B. (Rob) Scott
Mr. Robert B. (Rob) Scott
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Neil P. Ayotte, Esq.
Mr. Neil P. Ayotte, Esq.
Senior Vice President, General Counsel, Secretary and Chief Compliance Officer
Senior Vice President, General Counsel, Secretary and Chief Compliance Officer
--
--
Dr. Maria Rosa Costanzo, M.D.
Dr. Maria Rosa Costanzo, M.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: 17 hours ago
Updated: 17 hours ago
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Geode Capital Management, L.L.C.
0.78%
Virtu Americas LLC
0.62%
Citadel Advisors LLC
0.45%
Two Sigma Investments, LP
0.42%
XTX Markets LLC
0.37%
Other
97.36%
Shareholders
Shareholders
Proportion
Geode Capital Management, L.L.C.
0.78%
Virtu Americas LLC
0.62%
Citadel Advisors LLC
0.45%
Two Sigma Investments, LP
0.42%
XTX Markets LLC
0.37%
Other
97.36%
Shareholder Types
Shareholders
Proportion
Hedge Fund
1.01%
Investment Advisor/Hedge Fund
0.83%
Research Firm
0.63%
Venture Capital
0.41%
Investment Advisor
0.34%
Individual Investor
0.03%
Other
96.77%
Institutional Shareholding
Updated: Tue, Mar 4
Updated: Tue, Mar 4
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q1
26
102.06K
2.33%
+29.99K
2024Q4
25
113.78K
2.60%
+73.44K
2024Q3
29
65.32K
2.68%
+45.76K
2024Q2
28
42.02K
3.15%
+30.15K
2024Q1
26
9.25K
4.91%
+1.97K
2023Q4
26
6.22K
6.75%
+3.61K
2023Q3
35
1.28K
4.82%
-1.76K
2023Q2
36
1.31K
5.00%
-797.00
2023Q1
36
712.00
4.39%
-1.50K
2022Q4
33
629.00
6.11%
-1.05K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Geode Capital Management, L.L.C.
30.81K
0.7%
+30.81K
--
Dec 31, 2024
Virtu Americas LLC
--
0%
-2.22K
-100.00%
Jun 30, 2024
Citadel Advisors LLC
11.77K
0.27%
+11.77K
--
Dec 31, 2024
Two Sigma Investments, LP
11.31K
0.26%
-2.32K
-17.04%
Dec 31, 2024
HRT Financial LP
--
0%
-15.13K
-100.00%
Dec 31, 2024
Tower Research Capital LLC
4.77K
0.11%
-1.58K
-24.87%
Dec 31, 2024
UBS Financial Services, Inc.
23.24K
0.53%
+23.24K
--
Dec 31, 2024
The Vanguard Group, Inc.
1.43K
0.03%
--
--
Jan 31, 2025
SBI Securities Co., Ltd.
547.00
0.01%
+547.00
--
Dec 31, 2024
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Jun 26, 2024
Merger
35<1
Jun 26, 2024
Merger
35<1
Jun 26, 2024
Merger
35<1
Jun 26, 2024
Merger
35<1
Dec 09, 2022
Merger
100<1
Dec 09, 2022
Merger
100<1
Date
Type
Ratio
Jun 26, 2024
Merger
35<1
Jun 26, 2024
Merger
35<1
Jun 26, 2024
Merger
35<1
Jun 26, 2024
Merger
35<1
Dec 09, 2022
Merger
100<1
Dec 09, 2022
Merger
100<1
Dec 09, 2022
Merger
100<1
Dec 09, 2022
Merger
100<1
Oct 17, 2020
Merger
30<1
Oct 17, 2020
Merger
30<1
View more
